Enhertu recommended for approval in the EU by CHMP for patients with HER2-mutant advanced non-small cell lung cancer
Recommendation based on DESTINY-Lung02 trial results which showed AstraZeneca and Daiichi Sankyo’s Enhertu achieved strong and durable tumour responses in previously treated HER2-mutant disease. Enhertu showed a confirmed objective response rate of 49% and median duration of response of 16.8 months. AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who